Trial Profile
A one year open-label extension study to assess long term safety and tolerability of omalizumab treatment in poorly controlled moderate to severe allergic asthma patients who participated in the 52-week CIGE24IA04E1 study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Sponsors Novartis
- 31 Jul 2007 New trial record.